Board meeting on 26 Oct 2026 to consider Q2 and H1 FY26 results

Revenue declinedNet loss reportedEBITDA margin compressionResults View source PDF Explain this filing

ASTEC · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.0%Reaction day

₹707.50

prior close

₹711.00

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-1.7%-0.4% vs market

Pesticides & Agrochemicals peers, median of 28sector-1.7%-0.4% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty Microcap 250 and 0.4 pts less than its Pesticides & Agrochemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

-0.3

15m

-0.8

30m

-0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.0-1.7-0.4-1.7-0.4

Next day

-7.0-4.2-2.8-3.7-3.3

-5.8-5.2-0.6-6.1+0.3

-6.6-7.4+0.8-8.4+1.8

-8.1-7.0-1.1-8.3+0.2

-8.8-5.5-3.4-7.3-1.6

-17.7-4.8-13.0-7.5-10.3

15d

—————

UpDownMarket · Nifty Microcap 250Sector · Pesticides & Agrochemicals peers, median of 28Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

The Board of Directors of Astec Lifesciences will meet on 26 October 2026 to consider and approve the Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended 30 September 2026, after review by the Audit Committee.

Likely market impact

Routine intimation. Investors should watch for the Q2 and H1 FY26 results announcement post 26 October 2026.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹72.02 Cr	₹73.72 Cr	−2.3%
Operating profit	−₹38.04 Cr	−₹25.52 Cr	loss widened
Profit after tax	−₹37.40 Cr	−₹24.42 Cr	loss widened
EBITDA margin	-27.5%	-9.1%	−18.4 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.